[1]
10.1038/icb.2014.114 : nature.com search: http://www.nature.com.ezproxy.library.qmul.ac.uk/search?exclude-collections=journals_palgrave%2Clab_animal&include-collections=journals_nature%2Ccrawled_content&order=date_desc&q=10.1038%2Ficb.2014.114&q_match=all&sp-a=sp1001702d&sp-m=0&sp-p-1=phrase&sp-sfvl-field=subject%7Cujournal&sp-x-1=ujournal&submit=go.
[2]
Amyotrophic Lateral Sclerosis — NEJM: http://www.nejm.org.ezproxy.library.qmul.ac.uk/doi/full/10.1056/NEJMra1603471.
[3]
Chronic Traumatic Encephalopathy in Athletes: Progressive Tauopathy After Repetitive Head Injury | Journal of Neuropathology & Experimental Neurology | Oxford Academic: https://academic-oup-com.ezproxy.library.qmul.ac.uk/jnen/article-lookup/doi/10.1097/NEN.0b013e3181a9d503.
[4]
Clarke, C.E. 2007. Parkinson’s disease. BMJ. 335, 7617 (Sep. 2007), 441–445. DOI:https://doi.org/10.1136/bmj.39289.437454.AD.
[5]
Current Perspectives on Traumatic Brain Injury: http://www.asha.org/Articles/Current-Perspectives-on-Traumatic-Brain-Injury/.
[6]
Endocannabinoid Signaling and Long-Term Synaptic Plasticity - annurev.physiol.010908.163149: http://www.annualreviews.org.ezproxy.library.qmul.ac.uk/doi/pdf/10.1146/annurev.physiol.010908.163149.
[7]
Endocannabinoid Signaling and Long-Term Synaptic Plasticity - annurev.physiol.010908.163149: http://www.annualreviews.org.ezproxy.library.qmul.ac.uk/doi/pdf/10.1146/annurev.physiol.010908.163149.
[8]
Jarskog, L.F. et al. 2007. Schizophrenia: New Pathological Insights and Therapies. Annual Review of Medicine. 58, 1 (Feb. 2007), 49–61. DOI:https://doi.org/10.1146/annurev.med.58.060904.084114.
[9]
Löscher, W. 2011. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure. 20, 5 (Jun. 2011), 359–368. DOI:https://doi.org/10.1016/j.seizure.2011.01.003.
[10]
Multiple Functions of Endocannabinoid Signaling in the Brain | Annual Review of Neuroscience: http://www.annualreviews.org.ezproxy.library.qmul.ac.uk/doi/10.1146/annurev-neuro-062111-150420.
[11]
Packer, A.M. et al. 2013. Targeting neurons and photons for optogenetics. Nature Neuroscience. 16, 7 (Jun. 2013), 805–815. DOI:https://doi.org/10.1038/nn.3427.
[12]
Serhan, C.N. 2007. Resolution Phase of Inflammation: Novel Endogenous Anti-Inflammatory and Proresolving Lipid Mediators and Pathways. Annual Review of Immunology. 25, 1 (Apr. 2007), 101–137. DOI:https://doi.org/10.1146/annurev.immunol.25.022106.141647.
[13]
Walker, S. et al. 2009. The management of epilepsy in pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology. 116, 6 (May 2009), 758–767. DOI:https://doi.org/10.1111/j.1471-0528.2009.02141.x.
[14]
Yokobori, S. et al. 2013. Biomarkers for the Clinical Differential Diagnosis in Traumatic Brain Injury-A Systematic Review. CNS Neuroscience & Therapeutics. 19, 8 (Aug. 2013), 556–565. DOI:https://doi.org/10.1111/cns.12127.
[15]
Zhai, S. et al. 2018. Striatal synapses, circuits, and Parkinson’s disease. Current Opinion in Neurobiology. 48, (Feb. 2018), 9–16. DOI:https://doi.org/10.1016/j.conb.2017.08.004.
[16]
A review on Alzheimer’s disease pathophysiology and its management: an update - ScienceDirect.
[17]
Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems - ScienceDirect.
[18]
Animal models for the study of perinatal hypoxic-ischemic encephalopathy: a critical analysis - ScienceDirect.
[19]
Animal models for the study of perinatal hypoxic-ischemic encephalopathy: a critical analysis - ScienceDirect.
[20]
Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson’s disease - ScienceDirect.
[21]
Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents - ScienceDirect.
[22]
Therapeutics of Alzheimer’s disease: Past, present and future - ScienceDirect.